Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations | Zendy

Julian G. Hurdle | Zendy; A. E. Heathcott | Zendy; Lei Yang | Zendy; Bing Chun Yan | Zendy; Richard Lee | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations

Author(s) -

Julian G. Hurdle,

A. E. Heathcott,

Lei Yang,

Bing Chun Yan,

Richard Lee

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr201

Subject(s) - clostridium difficile , antibiotics , metronidazole , vancomycin , microbiology and biotechnology , gastrointestinal tract , clostridium , absorption (acoustics) , bacteria , chemistry , staphylococcus aureus , biology , pharmacology , biochemistry , materials science , genetics , composite material

The stationary phase of Clostridium difficile, which is associated with the symptoms of the diarrhoeal disease, is refractory to antibiotic killing. The aim of this study was to explore whether probiotic-derived reutericyclin and related synthetic analogues could kill stationary phase C. difficile at concentrations achievable in the gastrointestinal tract.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research